NEW YORK (GenomeWeb) – SEngine Precision Medicine has inked an exclusive licensing agreement with the Fred Hutchinson Cancer Research Center to market a diagnostic test designed to aid in the personalization of cancer treatments.

The assay, called PARIS, combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.